GDC-1971

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Advanced Solid TumorsColorectal CancerMetastatic Solid TumorsNon-Small Cell Lung Cancer

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Active, not recruitingNCT04449874

Genentech, Inc.Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

Start: 2020-07-29End: 2027-12-31Target: 498Updated: 2026-08-28

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

CompletedNCT05487235

Genentech, Inc.Advanced Solid Tumors, Metastatic Solid Tumors

Start: 2022-08-17End: 2025-06-23Updated: 2025-07-03

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

CompletedNCT05954871

Genentech, Inc.Colorectal Cancer, Non-Small Cell Lung Cancer

Start: 2024-01-08End: 2025-09-16Updated: 2025-11-13

Related Papers

Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Journal of Clinical Oncology2025-07-0911 citations

Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with <i>KRAS G12C</i>-positive non-small cell lung cancer (NSCLC)

Cancer Research2025-04-25

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

2023-12-0594 citations

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation

New England Journal of Medicine2023-08-23252 citations

Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with <i>KRAS G12C</i> mutation

Cancer Research2023-04-1410 citations

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

Cancer Research2022-06-157 citations